A
NYSEAgilent Technologies Inc.
Price$136.15+17.64 (+14.94%)
2026-03-052026-06-08
News · 26 weeks70+171%
2025-12-142026-06-07
Mix4690d
- Insider17(37%)
- Other17(37%)
- SEC Filings6(13%)
- Leadership2(4%)
- Earnings2(4%)
- Dividends2(4%)
Latest news
25 items- INSIDERNew insider Downs Timothy Charles claimed ownership of 8,872 shares (SEC Form 3)3 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
- INSIDERPresident and CEO Mcdonnell Padraig covered exercise/tax liability with 418 shares, decreasing direct ownership by 0.63% to 65,842 units (SEC Form 4)4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
- PRAgilent, OpenAI, BCG Collaborate to Accelerate Customer-Focused, AI-Driven Scientific InnovationAgilent Technologies Inc. (NYSE:A) today announced a collaboration with OpenAI and Boston Consulting Group (BCG) to accelerate the deployment of artificial intelligence (AI) across the company's products, operations, and customer workflows. "AI is a top priority, and this partnership reflects both our ambition and our execution commitment — to build the enduring capability, operating model, and capacity required to consistently deliver AI‑driven innovation value for our customers," said Padraig McDonnell, president and CEO of Agilent. "Through this collaboration with OpenAI and BCG, we are accelerating deployment of AI across our business while advancing more intelligent instruments, soft
- PRAgilent Receives FDA Approval for Expanded Use of PD-L1 IHC 22C3 pharmDx on Dako Omnis in Esophageal Squamous Cell Carcinoma, Triple-Negative Breast Cancer, Cervical Cancer, and Gastric or Gastroesophageal Junction AdenocarcinomaApproval expands PD-L1 testing onto an automated workflow to support treatment decisions with KEYTRUDA® (pembrolizumab)¹,² Agilent Technologies Inc. (NYSE:A) today announced that the U.S. Food and Drug Administration (FDA) has approved the expanded use of PD-L1 IHC 22C3 pharmDx, Code GE006, for use on the Dako Omnis platform to aid in identifying patients in the United States with esophageal squamous cell carcinoma (ESCC)3, triple-negative breast cancer (TNBC)4, cervical cancer5, and gastric or gastroesophageal junction (GEJ) adenocarcinoma6, who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy. This approval expands access to PD-L1 testing across
- INSIDERDirector Dolsten Mikael sold $216,672 worth of shares (1,600 units at $135.42), decreasing direct ownership by 22% to 5,548 units (SEC Form 4)4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
- SECSEC Form 10-Q filed by Agilent Technologies Inc.10-Q - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)
- SECSEC Form SD filed by Agilent Technologies Inc.SD - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)
- ANALYSTAgilent upgraded by BofA Securities with a new price targetBofA Securities upgraded Agilent from Neutral to Buy and set a new price target of $145.00
- PRAgilent Introduces OpenLab Sync to Support Guided, Digital Execution in the LaboratoryAgilent Technologies Inc. (NYSE:A) today announced the introduction of OpenLab Sync, a new Lab Execution System (LES) that enables laboratories to digitally connect scientific workflows from method design through execution at the bench. OpenLab Sync extends Agilent's OpenLab laboratory informatics portfolio beyond traditional data and sample management, enabling guided, standardized, and traceable execution of laboratory work in regulated environments. As laboratories face increasing regulatory scrutiny, workforce turnover, and pressure to standardize operations across sites, many continue to rely on static, paper-based procedures that can introduce variability and risk. OpenLab Sync addr
- SECAgilent Technologies Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits8-K - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)
- PRAgilent Reports Second-Quarter Fiscal Year 2026 Financial ResultsDelivers strong Q2 results and raises FY26 revenue growth, margin expansion, and non-GAAP EPS(4) guidance on continued operational momentum Second-quarter fiscal year 2026 Revenue of $1.83 billion for the second quarter ended April 30, 2026, representing growth of 10.0% reported and up 6.3% core(1) compared with the second quarter of 2025. GAAP operating margin of 21.7%; non-GAAP operating margin(2) of 26.4% expanded by 130 basis points year-over-year and 180 basis points sequentially. GAAP net income of $339 million; earnings per share (EPS) of $1.20, an increase of 60% from the second quarter of 2025. Non-GAAP net income(3) of $423 million; non-GAAP EPS(3) of $1.49, an incre
- ANALYSTRBC Capital Mkts initiated coverage on Agilent with a new price targetRBC Capital Mkts initiated coverage of Agilent with a rating of Outperform and set a new price target of $153.00
- PRAgilent Launches Multi-Attribute Method (MAM) Solution for BioPharma Quality ControlAgilent Technologies Inc. (NYSE:A) today announced the release of a new multi-attribute method (MAM) workflow designed to help pharmaceutical and biopharmaceutical quality control (QC) laboratories implement liquid chromatography high-resolution mass spectrometry (LC/HRMS) in routine, regulated testing environments. The Agilent MAM solution brings together software, instrumentation, columns, consumables and standards to address practical and operational barriers that have historically limited the use of LC/HRMS in QC environments. The workflow is designed to support laboratories applying MAM to monitor critical quality attributes during late-stage development and commercial manufacturing.
- PRAgilent Launches New GC Systems with GC Assist to Improve Laboratory Efficiency and Data QualityNew 8890B and 8860B gas chromatographs integrate intelligent monitoring and remote diagnostics Agilent Technologies Inc. (NYSE:A) today announced the launch of the new 8890B GC and 8860B GC with GC Assist. GC Assist is the new, advanced instrument intelligence that provides system monitoring, built-in troubleshooting, and remote connectivity to analytical instrumentation within the laboratory's secure network. These systems enable higher performance and productivity across gas chromatography analyses. The new systems are designed to help laboratories reduce unplanned downtime, improve data quality, and operate more efficiently by combining updated GC hardware with integrated system moni
- PRAgilent Unveils the 9500 ICP-MS: Redefining Trace Element AnalysisNext-generation ICP-MS/MS delivers faster measurements, simplified workflows, and easier access to advanced elemental analysis Agilent Technologies Inc. (NYSE:A) today announced the launch of the Agilent 9500 Triple Quadrupole ICP-MS, a next-generation inductively coupled plasma mass spectrometry system designed to help single quadrupole ICP-MS laboratories more easily transition to triple quadrupole technology for advanced trace elemental analysis. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522685512/en/Agilent 9500 Triple Quadrupole ICP-MS System As testing demands grow more complex and skilled resources remain limite
- INSIDERSenior Vice President Buckner Michael Steven was granted 8,872 shares, increasing direct ownership by 59,147% to 8,887 units (SEC Form 4)4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
- PRAgilent Launches 1290 Infinity III Fluorescence Detector for Confident Trace Analysis at UHPLC SpeedAgilent Technologies Inc. (NYSE:A) today announced the launch of the Agilent 1290 Infinity III Fluorescence Detector (FLD), a new fluorescence detector designed specifically for modern ultra-high-performance liquid chromatography (UHPLC) workflows. The detector extends fluorescence detection into the UHPLC era by combining ultra-trace sensitivity, UHPLC-ready chromatographic performance, and routine-ready ease of use. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521579990/en/1290 Infinity III Fluorescence Detector with front-access service design. Designed for use as a standalone detector or in-line with LC/MS systems, the
- PRAgilent Announces Cash Dividend of 25.5 Cents per ShareAgilent Technologies Inc. (NYSE:A) today announced a quarterly dividend of 25.5 cents per share of common stock. The quarterly dividend will be paid on July 22, 2026, to all shareholders of record as of the close of business on June 30, 2026. The timing and amounts of future dividends are subject to the determination and approval of Agilent's board of directors. About Agilent Technologies Agilent Technologies, Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise that provide tru
- PRAgilent to Supply Next Generation Alarm Resolution Technology to U.S. Airport Security Screening Checkpoints ahead of FIFA World Cup 2026Agilent has been awarded a contract by the Transportation Security Administration (TSA) to supply its Bulk Resolution Technology (BRT) systems to passenger security checkpoints at FIFA World Cup U.S. host city airports Agilent Technologies Inc. (NYSE:A) today announced that it has been awarded a contract by the Transportation Security Administration (TSA) and will deploy its new Bulk Alarm Resolution Technology (BRT) to security checkpoints at FIFA World Cup U.S. host city airports with the capabilities to screen larger quantities of liquids, powders, and solids commonly encountered in airport security screening operations. "Agilent is thrilled to have been selected by TSA to modernize
- INSIDERSenior Vice President May Simon covered exercise/tax liability with 368 shares, decreasing direct ownership by 3% to 14,015 units (SEC Form 4)4 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
- PRAgilent to Participate in Jefferies Global Healthcare ConferenceAgilent Technologies Inc. (NYSE:A) today announced that CEO Padraig McDonnell and CFO Adam Elinoff will participate in a fireside chat at the Jefferies Global Healthcare Conference. The event is scheduled for 9:20 EDT on Wednesday, June 3, 2026, in New York City. A live audio webcast and replay of the presentation will be available through Agilent's Investor Relations website. About Agilent Technologies Agilent Technologies, Inc. (NYSE:A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent's full range of solutions includes instruments, software, services, and expertise tha
- INSIDERNew insider Buckner Michael Steven claimed ownership of 15 shares (SEC Form 3)3 - AGILENT TECHNOLOGIES, INC. (0001090872) (Issuer)
- SECAgilent Technologies Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - AGILENT TECHNOLOGIES, INC. (0001090872) (Filer)
- PRAgilent Names Michael Buckner as Chief Legal OfficerAgilent Technologies Inc. (NYSE:A) today announced the appointment of Michael Buckner as chief legal officer, effective today. Buckner brings nearly three decades of experience as a senior global legal executive, with a proven track record of building and leading high-performing teams and deep expertise in complex transactions and regulatory environments. "We are thrilled to welcome Michael to the Agilent team," said Padraig McDonnell, Agilent president and CEO. "His experience leading global legal organizations, combined with his expertise across governance, compliance and regulatory matters, will play a key role as we continue to advance our strategy and deliver for our customers and
- PRBloomberg Expands Global Equity Offering with Australia Domestic Equity IndicesNew indices deliver transparent, comprehensive access to Australian equities for benchmarking and investment applicationsNEW YORK and SYDNEY, April 28, 2026 /PRNewswire/ -- Bloomberg today announced the launch of the new Bloomberg Australia Domestic Equity Indices. The indices are designed to provide broad and investable exposure to Australian equities for benchmarking, asset allocation, and creation of financial products for both institutional and retail investors. "The launch of our Australia Domestic Equity Indices represents a natural evolution of our offering, building on a
A FAQ
8 questionsWhat does Agilent Technologies Inc. do?
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid and gas chromatography systems and components; liquid and gas chromatography mass spectrometry systems; inductively coupled plasma mass and optical emission spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems...Where does A stock trade?
Agilent Technologies Inc. (A) is listed on NYSE.What sector and industry is A in?
Agilent Technologies Inc. operates in the Industrials sector, Biotechnology: Laboratory Analytical Instruments industry.When did Agilent Technologies Inc. go public?
Agilent Technologies Inc. (A) completed its IPO in 1999.Does A pay a dividend?
Yes. A's next ex-dividend date is 2026-06-30 with a declared cash dividend of $0.26 per share, payable 2026-07-22.What are analysts saying about A?
Agilent Technologies Inc. has had 8 recent analyst actions on file. The most recent action was from BofA Securities: Buy on 2026-05-28.What companies are similar to A?
Notable peers in the same industry include TMO (Thermo Fisher Scientific Inc), WAT (Waters Corporation), PKI (PerkinElmer Inc.). Compare A side-by-side with any of them on Quantisnow.How can I track A on Quantisnow?
Quantisnow aggregates Agilent Technologies Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow A to receive live email and push alerts on every new disclosure.